HUE054226T2 - Módszerek és készítmények az ischaemia reperfúziós károsodás megelõzésére a szervekben - Google Patents

Módszerek és készítmények az ischaemia reperfúziós károsodás megelõzésére a szervekben

Info

Publication number
HUE054226T2
HUE054226T2 HUE18183735A HUE18183735A HUE054226T2 HU E054226 T2 HUE054226 T2 HU E054226T2 HU E18183735 A HUE18183735 A HU E18183735A HU E18183735 A HUE18183735 A HU E18183735A HU E054226 T2 HUE054226 T2 HU E054226T2
Authority
HU
Hungary
Prior art keywords
organs
compositions
methods
reperfusion injury
ischemia reperfusion
Prior art date
Application number
HUE18183735A
Other languages
English (en)
Hungarian (hu)
Inventor
Elizabeth C Squiers
Shai Erlich
Daniel Rothenstein
Nir Sharon
Daniel J Odenheimer
Elena Feinstein
Original Assignee
Quark Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quark Pharmaceuticals Inc filed Critical Quark Pharmaceuticals Inc
Publication of HUE054226T2 publication Critical patent/HUE054226T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/712Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/317Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/319Chemical structure of the backbone linked by 2'-5' linkages, i.e. having a free 3'-position
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3212'-O-R Modification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • C12N2310/3515Lipophilic moiety, e.g. cholesterol
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/352Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521Methyl
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HUE18183735A 2014-05-29 2015-05-27 Módszerek és készítmények az ischaemia reperfúziós károsodás megelõzésére a szervekben HUE054226T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462004239P 2014-05-29 2014-05-29

Publications (1)

Publication Number Publication Date
HUE054226T2 true HUE054226T2 (hu) 2021-08-30

Family

ID=53398201

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE18183735A HUE054226T2 (hu) 2014-05-29 2015-05-27 Módszerek és készítmények az ischaemia reperfúziós károsodás megelõzésére a szervekben
HUE15729289A HUE040092T2 (hu) 2014-05-29 2015-05-27 Módszerek és készítmények az iszkémia reperfúziós sérülés megelõzésére a szervekben

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE15729289A HUE040092T2 (hu) 2014-05-29 2015-05-27 Módszerek és készítmények az iszkémia reperfúziós sérülés megelõzésére a szervekben

Country Status (18)

Country Link
US (3) US20170081665A1 (enExample)
EP (2) EP3444349B1 (enExample)
JP (2) JP2017521374A (enExample)
KR (1) KR20170007492A (enExample)
CN (2) CN106661579B (enExample)
AU (1) AU2015267160B2 (enExample)
BR (1) BR112016028009A2 (enExample)
CA (1) CA2949109A1 (enExample)
DK (2) DK3444349T3 (enExample)
ES (2) ES2683869T3 (enExample)
HU (2) HUE054226T2 (enExample)
IL (2) IL248912A0 (enExample)
LT (2) LT3149172T (enExample)
MX (2) MX373950B (enExample)
PL (2) PL3149172T3 (enExample)
PT (2) PT3444349T (enExample)
SI (2) SI3149172T1 (enExample)
WO (1) WO2015183842A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110177544A (zh) 2016-11-29 2019-08-27 普尔泰克健康有限公司 用于递送治疗剂的外泌体
EP3737388A4 (en) * 2018-01-12 2021-10-06 University of Massachusetts Methods for preventing graft ischemia reperfusion injury during ex vivo machine perfusion preservation
GB202016863D0 (en) * 2020-10-23 2020-12-09 Causeway Therapeutics Ltd Microrna-29 compounds, compositions and uses in therapy
AU2022418939A1 (en) * 2021-12-22 2024-03-21 Na Vaccine Institute Composition for preventing or treating ischemia-reperfusion injury and use thereof
KR20240154159A (ko) * 2023-04-17 2024-10-25 재단법인 아산사회복지재단 miR-223을 유효성분으로 포함하는 간 손상 예방 또는 치료용 조성물
CN118460648B (zh) * 2024-07-10 2025-01-28 凯莱英医药集团(天津)股份有限公司 一种qpi-1002的制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5861254A (en) 1997-01-31 1999-01-19 Nexstar Pharmaceuticals, Inc. Flow cell SELEX
JPH06508022A (ja) 1991-02-21 1994-09-14 ギリアド サイエンシズ,インコーポレイテッド 生体分子に特異的なアプタマーおよび生産方法
US5756291A (en) 1992-08-21 1998-05-26 Gilead Sciences, Inc. Aptamers specific for biomolecules and methods of making
ATE204325T1 (de) 1993-04-29 2001-09-15 Unilever Nv Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae
CA2360671A1 (en) 1999-01-29 2000-08-03 The Board Of Trustees Of The University Of Illinois P53 inhibitors and therapeutic use of the same
US6376190B1 (en) 2000-09-22 2002-04-23 Somalogic, Inc. Modified SELEX processes without purified protein
US20060105975A1 (en) 2004-04-19 2006-05-18 Shannon Pendergrast Aptamer-mediated intracellular delivery of therapeutic oligonucleotides
RU2584609C2 (ru) * 2004-09-28 2016-05-20 Кварк Фармасьютикалс, Инк. Олигорибонуклеотиды и способы их применения для лечения острой почечной недостаточности
US8362229B2 (en) 2006-02-08 2013-01-29 Quark Pharmaceuticals, Inc. Tandem siRNAS
US7910566B2 (en) * 2006-03-09 2011-03-22 Quark Pharmaceuticals Inc. Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA
PT2170403E (pt) 2007-06-27 2014-07-17 Quark Pharmaceuticals Inc Composições e métodos para inibição da expressão de genes pró-apoptóticos
US8614309B2 (en) * 2007-10-03 2013-12-24 Quark Pharmaceuticals, Inc. Double-stranded RNA directed to CASP2 and methods of use thereof
WO2009155504A2 (en) * 2008-06-20 2009-12-23 The Children's Medical Center Corporation Methods for the modulation of angiogenesis
JP2012529430A (ja) 2009-06-08 2012-11-22 クォーク ファーマシューティカルズ インコーポレーティッド 慢性腎臓疾患の治療方法
AU2010324658A1 (en) 2009-11-26 2012-05-03 Quark Pharmaceuticals, Inc. siRNA compounds comprising terminal substitutions
WO2011084193A1 (en) 2010-01-07 2011-07-14 Quark Pharmaceuticals, Inc. Oligonucleotide compounds comprising non-nucleotide overhangs
WO2011138966A1 (ja) 2010-05-06 2011-11-10 ダイヤニトリックス株式会社 微生物触媒を用いたアクリルアミドの製造方法
CA2818046A1 (en) * 2010-11-17 2012-05-24 The University Of North Carolina At Chapel Hill Protection of renal tissues from ischemia through inhibition of the proliferative kinases cdk4 and cdk6
AU2011338682B2 (en) 2010-12-06 2017-04-27 Quark Pharmaceuticals, Inc. Double stranded oligonucleotide compounds comprising threose modifications
US9176487B2 (en) * 2011-10-24 2015-11-03 Mayo Foundation For Medical Education And Research Methods and materials for reducing the risk of infections
EP2895608B1 (en) * 2012-09-12 2018-12-05 Quark Pharmaceuticals, Inc. Double-stranded oligonucleotide molecules to p53 and methods of use thereof

Also Published As

Publication number Publication date
DK3444349T3 (da) 2021-04-12
KR20170007492A (ko) 2017-01-18
JP2020128383A (ja) 2020-08-27
MX373950B (es) 2020-07-13
EP3149172B1 (en) 2018-07-18
IL278144A (en) 2020-11-30
EP3444349A1 (en) 2019-02-20
US20180305696A1 (en) 2018-10-25
WO2015183842A1 (en) 2015-12-03
SI3444349T1 (sl) 2021-07-30
EP3444349B1 (en) 2021-01-06
US20170081665A1 (en) 2017-03-23
ES2683869T3 (es) 2018-09-28
LT3149172T (lt) 2018-09-10
US9868953B2 (en) 2018-01-16
HUE040092T2 (hu) 2019-02-28
PT3444349T (pt) 2021-04-06
AU2015267160A8 (en) 2016-12-08
IL278144B (en) 2021-07-29
LT3444349T (lt) 2021-04-12
CN112410336A (zh) 2021-02-26
PT3149172T (pt) 2018-10-08
MX2020005794A (es) 2020-10-28
EP3149172A1 (en) 2017-04-05
ES2862185T3 (es) 2021-10-07
PL3149172T3 (pl) 2018-10-31
BR112016028009A2 (pt) 2018-02-20
AU2015267160A1 (en) 2016-12-01
US20170335327A1 (en) 2017-11-23
AU2015267160B2 (en) 2021-07-29
SI3149172T1 (sl) 2018-10-30
CN106661579A (zh) 2017-05-10
CN106661579B (zh) 2020-12-04
PL3444349T3 (pl) 2021-06-28
IL248912A0 (en) 2017-01-31
JP2017521374A (ja) 2017-08-03
MX2016015635A (es) 2017-04-25
CA2949109A1 (en) 2015-12-03
DK3149172T3 (en) 2018-08-20

Similar Documents

Publication Publication Date Title
HUE043297T2 (hu) Jelölõsáv és hozzá való eljárás
IL278144A (en) Compositions for the prevention of organ damage resulting from ischemia-reperfusion
EP2982844A4 (en) CHARGER AND SHIP
PT3060608T (pt) Pigmentos de dispersão com elevada resistência em molhado e suas misturas
IL264760B1 (en) Regional ischemia/reperfusion injury
DE102015111641A8 (de) Dachblech-an-Karosserieseite-Haltegurt
DK3107374T3 (da) Hybride bw-type-svampestammer og -linjer og fremgangsmåder derfor og anvendelser derfor
GB201418071D0 (en) Improvement in or relation to fishing
FI20145740A7 (fi) Sovitelma puomistossa
GB201519773D0 (en) Improvements in and relating to tree stands
GB201404683D0 (en) Engineering in seafaring
GB201413796D0 (en) Improvements in or relating to veterinarian collars
ES1109107Y (es) Embocadura para nasas de pesca y recipiente portacebo extraible
TH1501007009A (th) เม็ด n-อะซีติลซิสเทอีนที่สามารถกลืนได้
UA30890S (uk) Емблема
UA30892S (uk) Емблема
UA30891S (uk) Емблема
UA30889S (uk) Емблема
UA30888S (uk) Емблема
UA30887S (uk) Емблема
UA30563S (uk) Емблема
UA30782S (uk) Емблема
UA30783S (uk) Емблема
UA30655S (uk) Емблема
UA30651S (uk) Емблема